Octant Bio
Octant Bio discovers and develops small-molecule drugs by measuring how human cell receptors respond to compounds and designing molecules that modulate multiple pathways. It uses synthetic biology and genome engineering to create engineered cells, high-throughput chemistry and automation for compound synthesis and screening, and next-generation sequencing plus computational tools and machine learning to profile thousands of receptor pathways. The company operates as a therapeutics-focused biotech with an internal discovery platform targeting rare disease, oncology, and immunology. Octant collaborates with research partners and scales discovery through automated, high-throughput workflows and predictive modeling.
Octant Bio
Octant Bio discovers and develops small-molecule drugs by measuring how human cell receptors respond to compounds and designing molecules that modulate multiple pathways. It uses synthetic biology and genome engineering to create engineered cells, high-throughput chemistry and automation for compound synthesis and screening, and next-generation sequencing plus computational tools and machine learning to profile thousands of receptor pathways. The company operates as a therapeutics-focused biotech with an internal discovery platform targeting rare disease, oncology, and immunology. Octant collaborates with research partners and scales discovery through automated, high-throughput workflows and predictive modeling.
TL;DR
What they do: AI- and synthetic-biology-enabled small-molecule drug discovery using the Navigator platform
Therapeutic focus: Protein misfolding/mistrafficking diseases (e.g., RHO-associated adRP, Fabry) and oncology
Founded: 2017
Latest known funding: Series B announced Apr 21, 2022
Headcount (approx.): 70 employees
Company Overview
Problem Domain
Small-molecule therapeutics for protein misfolding/mistrafficking diseases and oncology
Founded
2017
Industry
Biotechnology
Tech Stack
Funding Track Record
80000000
Bristol-Myers Squibb participated and signed a drug discovery partnership
Investor Signal
“Company has attracted leading life-science VC firms and strategic pharma participation (e.g., Andreessen Horowitz, Catalio Capital Management, Bristol-Myers Squibb)”